These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38182100)

  • 1. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
    Hoste E; Haufroid V; Deldicque L; Balligand JL; Elens L
    Clin Biochem; 2024 Feb; 124():110707. PubMed ID: 38182100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
    Turner RM; Fontana V; Zhang JE; Carr D; Yin P; FitzGerald R; Morris AP; Pirmohamed M
    Clin Pharmacol Ther; 2020 Aug; 108(2):287-297. PubMed ID: 32128760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N; Indumathi B; Katkam SK; Kutala VK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
    Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
    Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
    Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
    León-Cachón RBR; Bamford AD; Meester I; Barrera-Saldaña HA; Gómez-Silva M; Bustos MFG
    Sci Rep; 2020 Jun; 10(1):8900. PubMed ID: 32483134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms.
    Lauritzen T; Munkhaugen J; Peersen K; Kristiansen O; Sverre E; Nebauer SD; Villseth M; Andersen AM; Svarstad AC; Jensen EP; Bergan S; Husebye E; Vethe NT
    Clin Pharmacol Ther; 2023 Apr; 113(4):887-895. PubMed ID: 36622792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines.
    Hoste E; Paquot A; Panin N; Horion S; El Hamdaoui H; Muccioli GG; Haufroid V; Elens L
    Ther Drug Monit; 2023 Jun; 45(3):400-408. PubMed ID: 36253893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis.
    Du Y; Wang S; Chen Z; Sun S; Zhao Z; Li X
    Curr Pharm Des; 2018; 24(34):4044-4050. PubMed ID: 30569848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.
    Bakar NS; Neely D; Avery P; Brown C; Daly AK; Kamali F
    Clin Pharmacol Ther; 2018 Jul; 104(1):178-187. PubMed ID: 28940218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
    Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
    Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of
    Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
    Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
    Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
    Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.